13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001974915
Total reported value
$4.3B
$4.3B
72 檔
13.1%
As reported in its official Q2 2025 Form 13F filing, Vestal Point Capital, LP's tracked investment portfolio stood at $4.3B with 72 total positions.
During Q2 2025, Vestal Point Capital, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | Stock-Other | 9.53% | — | +15.17% | |
| 2 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 6.70% | — | — | |
| 3 | CYTK | Cytokinetics Inc | Stock-Healthcare | 5.18% | -0.55% | EXIT | |
| 4 | NUVL | Nuvalent Inc-a | Stock-Other | 4.32% | -1.38% | EXIT | |
| 5 | VERA | Vera Therapeutics Inc | Stock-Other | 3.85% | -1.54% | EXIT | |
| 6 | AM6 | Amicus Therapeutics Inc | Stock-Other | 3.59% | — | +178.36% | |
| 7 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.30% | -0.05% | +53.85% | |
| 8 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 3.14% | — | +88.23% | |
| 9 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.80% | -1.82% | EXIT | |
| 10 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 2.78% | -1.04% | EXIT | |
| 11 | GEHC | GE Healthcare Technology | Stock-Healthcare | 2.73% | +0.17% | +242.92% | |
| 12 | QURE | uniQure N.V. | Stock-Other | 2.72% | +0.85% | -22.80% | |
| 13 | BCAX | Bicara Therapeutics Inc | Stock-Other | 2.45% | +0.62% | +80.57% | |
| 14 | ALC | Alcon Inc. | Stock-Healthcare | 2.44% | -0.91% | — | |
| 15 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.32% | -4.49% | — | |
| 16 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.27% | — | — | |
| 17 | EXK | Exact Sciences CORP | Stock-Materials | 1.96% | — | — | |
| 18 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.87% | -1.09% | EXIT | |
| 19 | ASND | Ascendis Pharma A/S | Stock-Other | 1.82% | -2.40% | EXIT | |
| 20 | ✓ | Immatics NV | Stock-Other | 1.77% | -0.24% | -13.11% | |
| 21 | GERN | Geron CORP | Stock-Other | 1.76% | -0.11% | EXIT | |
| 22 | GMED | Globus Medical Inc - A | Stock-Healthcare | 1.55% | +0.10% | +150.00% | |
| 23 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.45% | +2.41% | — | |
| 24 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.37% | — | +175.00% | |
| 25 | TYRA | Tyra Biosciences Inc | Stock-Other | 1.34% | -0.06% | EXIT | |
| 26 | SVRA | Savara Inc | Stock-Other | 1.32% | -0.01% | +0.14% | |
| 27 | COO | Cooper Cos Inc/the | Stock-Healthcare | 1.31% | — | — | |
| 28 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.31% | — | -32.92% | |
| 29 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.28% | — | -0.90% | |
| 30 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.28% | — | +8.18% | |
| 31 | ABT | Abbott Laboratories | Stock-Healthcare | 1.25% | +2.97% | NEW | |
| 32 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.24% | — | — | |
| 33 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.20% | +1.74% | +77.69% | |
| 34 | COGT | Cogent Biosciences Inc | Stock-Other | 1.16% | -1.32% | EXIT | |
| 35 | BRKR | Bruker CORP | Stock-Healthcare | 1.08% | — | +66.67% | |
| 36 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.04% | — | — | |
| 37 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 1.03% | — | +15.47% | |
| 38 | MDT | Medtronic plc | Stock-Healthcare | 0.89% | — | — | |
| 39 | PRGO | Perrigo Company plc | Stock-Healthcare | 0.88% | — | +6.36% | |
| 40 | ZYME | Zymeworks Inc | Stock-Other | 0.76% | — | +130.00% | |
| 41 | BDTX | Black Diamond Therapeutics I | Stock-Other | 0.73% | — | — | |
| 42 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.68% | -0.25% | +184.11% | |
| 43 | ✓ | Nyxoah S A | Stock-Other | 0.55% | -0.04% | -39.54% | |
| 44 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 0.53% | — | — | |
| 45 | DHR | Danaher CORP | Stock-Healthcare | 0.52% | — | -60.00% | |
| 46 | BBNX | Beta Bionics Inc | Stock-Other | 0.42% | -0.03% | — | |
| 47 | IRON | Disc Medicine Inc | Stock-Other | 0.39% | +1.40% | — | |
| 48 | SLDB | Solid Biosciences Inc | Stock-Other | 0.39% | -0.51% | -14.17% | |
| 49 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.36% | +0.84% | — | |
| 50 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.36% | -0.28% | -59.58% |
According to official SEC Form 13F filings, Vestal Point Capital, LP reported a total U.S. public equity portfolio value of $4.3B across 72 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ACLXGBX, JAZZ, CYTK) accounted for 13.1% of total reported equity market value during Q2 2025.
During Q2 2025, Vestal Point Capital, LP's top holdings by market value included ACLXGBX (9.5%)、JAZZ (6.7%)、CYTK (5.2%). The largest single position, ACLXGBX, represented 9.5% of total portfolio value.
In Q2 2025, Vestal Point Capital, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.